Prateek Mendiratta, MD
Hematology & Oncology · Beachwood, OHNPI 1104960525
Payments from drug & device makers
Across 425 payments — averaging $4720.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1.5M
- Seagen Inc.$225K
- AstraZeneca$88K
- Bayer$83K
- Astellas Pharma US Inc$33K
- Pfizer$26K
- plus $8K from 22 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 134 | $1,542,426 |
| Seagen Inc. | 98 | $225,364 |
| AstraZeneca | 75 | $87,573 |
| Bayer | 12 | $82,982 |
| Astellas Pharma US Inc | 30 | $33,275 |
| Pfizer | 16 | $25,964 |
| Eisai Inc. | 5 | $2,360 |
| Sanofi | 3 | $1,864 |
| Array Biopharma Inc | 2 | $1,818 |
| Johnson & Johnson | 6 | $1,396 |
| Novartis | 15 | $298 |
| Tempus AI, Inc | 2 | $118 |
| AbbVie | 4 | $110 |
| Blue Earth Diagnostics | 1 | $92 |
| E.r. Squibb & Sons, L.L.C. | 4 | $70 |
| Astellas Pharma Global Development | 2 | $46 |
| Tolmar Pharmaceuticals, Inc. | 1 | $42 |
| Janssen Scientific Affairs, LLC | 2 | $34 |
| Amgen | 1 | $34 |
| Ipsen Biopharmaceuticals, Inc | 2 | $33 |
| Genentech USA, Inc. | 2 | $33 |
| Sumitomo Pharma America, Inc. | 2 | $30 |
| Gilead | 1 | $23 |
| Geron Corporation | 1 | $18 |
| Incyte Corporation | 1 | $17 |
| Genmab U.S., Inc. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Myovant Sciences Inc. | 1 | $13 |
How this compares
$2,006,064 in reported general payments places this provider in the 90th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Beachwood
- Afshin DowlatiCleveland$25.1M
- Brian HillCleveland$11.6M
- Trisha Wise-DraperCincinnati$9.8M
- Davendra SohalCincinnati$8.6M
- Christopher HoimesCleveland$7.5M
- Balazs HalmosCleveland$7M
- David WaterhouseCincinnati$5.7M
- Dale ShepardCleveland$5.1M
- Paolo CaimiCleveland$4.2M
- Allison WinterCleveland$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.